Serum Institute of India’s (SII) Cervavac - a quadrivalent human papillomavirus (qHPV) vaccine - is likely to be the first indigenous qHPV vaccine to be approved in India, according to GlobalData.
The data and analytics company notes that this will not only make the drug more affordable to Indians, but it will significantly improve the overall penetration and help address the growing number of cervical cancer cases in the country.
qHPV vaccines help protect against cancers caused by HPV such as cervical cancer. According to GlobalData’s Pharmaceutical Intelligence Center, the number of diagnosed prevalent cases of cervical cancer in India is estimated to grow at a compound annual growth rate (CAGR) of 3.11%, from 424,341 in 2021 to 540,435 in 2030.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze